Anchor the design in biology.
Target expression and disease context shape the opportunity before a candidate is built.
Skip to content
01 / CONTEXT
02 / RECOGNITION
03 / CHEMISTRY
04 / STOICHIOMETRY
05 / BIOLOGICAL FIT
ADC INTELLIGENT DESIGN PLATFORM
Design the molecule. Know the biology.
Molecular engineering, predictive biology and experimental evidence in one connected design loop for antibody–drug conjugate programs.
From molecular architecture to biological fit
THE NOMADC ADVANTAGE
A promising ADC is more than its parts. Its chemistry, target and biological setting must work together.
Molecular design / 01
Precision at every interface.
We connect target selection, conjugation chemistry, cellular response and clinical evidence in one deliberate design process.
01Antibody
02Linker + payload
03Antigen on target cell
TARGET CONTEXTBiology defines the design space.
Define the targeting architecture.
Binder selection and conjugation site establish how a candidate recognizes its target.
Tune the linker–payload system.
Stability, release chemistry and payload mechanism are engineered as connected variables.
Shape payload density.
DAR is considered alongside exposure, molecular properties and target biology.
Interrogate biological fit.
From cell-surface engagement to measured response, evidence informs the next design decision.
INTEGRATED INTELLIGENCE / 02
One connected discovery environment.
Biological context, predictive prioritization and molecular generation share a common decision framework.
BIOLOGY ATLAS / INTERFACE PREVIEW
See the biology behind the target.
Bring antigen expression and cancer model evidence into focus before committing to a design path.
Target and model discoveryExpression and multiomics contextTranslational relevance
⌕ Explore a target or cell model ⌘ K
TARGET CONTEXTHER2 / ERBB2
Receptor tyrosine kinase
CELL MODELSK-OV-3
Ovarian cancer · example context
RNA · Protein · Response
INTERFACE PREVIEW
PREDICTION / INTERFACE PREVIEW
Prioritize with context.
Compare molecular choices against tumor biology and surface uncertainty before moving to the bench.
ADC and cell contextActivity and expression signalsEvidence for prioritization
Explore AMM‑INVITRO ↗ANTIGENHER2
CELL MODELSK-OV-3
LINKER–PAYLOADvc–MMAE
DAR STRATEGYModel input
DESIGN COMPARISONConnect molecular choices to biological context
A future workspace for comparative evidence and uncertainty.
INTERFACE PREVIEW
GENERATION / INTERFACE PREVIEW
Explore constrained molecular space.
Explore linker designs around fixed anchors, payload identity and biological objectives.
Constraint aware designRanked candidatesSynthesis accessible
01 / INPUTAnchor + payloadFixed molecular endpoints
→02 / DESIGNLinker spaceConstrained exploration
→03 / REVIEWCandidate setRanked for evaluation
Biology awareConjugation awareProperty aware
INTERFACE PREVIEW
THE CLOSED LOOP / 03
The experiment becomes the next design input.
NOMADC links in silico design with in vitro evidence. Each cycle challenges the model, sharpens the hypothesis and informs the next candidate.
ONE LEARNING SYSTEMDesign ↔ evidenceModel · measure · refine
01 / IN SILICO
Design with intent.
Integrate structure, target biology and design constraints to nominate candidates.
02 / IN VITRO
Test the hypothesis.
Measure response and interrogate where predictions hold—or fail.
03 / BACK TO DESIGN
Learn and refine.
Feed experimental evidence into the next round of prioritization.
NOMADC Therapeutics / 04
A more deliberate ADC future.
We are building a discovery engine for co-development partnerships and proprietary ADC programs—grounded in the dialogue between computation and experiment.
NOMADC THERAPEUTICS FILM · 04:48
BUILD WITH NOMADC / 05
Let's build the next ADC.
We welcome conversations with biopharma partners, researchers and investors aligned with a more integrated approach to ADC discovery.
Start a conversation